Cargando…

Diagnostic Value of Preoperative uPAR-PET/CT in Regional Lymph Node Staging of Oral and Oropharyngeal Squamous Cell Carcinoma: A Prospective Phase II Trial

The detection of lymph node metastases is a major challenge in oral and oropharyngeal squamous cell carcinoma (OSCC and OPSCC). (68)Ga-NOTA-AE105 is a novel positron emission tomography (PET) radioligand with high affinity to urokinase-type plasminogen activator receptor (uPAR), a receptor expressed...

Descripción completa

Detalles Bibliográficos
Autores principales: Lawaetz, Mads, Christensen, Anders, Juhl, Karina, Lelkaitis, Giedrius, Karnov, Kirstine, Carlsen, Esben Andreas, Charabi, Birgitte W., Loft, Annika, Czyzewska, Dorota, von Buchwald, Christian, Kjaer, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649042/
https://www.ncbi.nlm.nih.gov/pubmed/37958201
http://dx.doi.org/10.3390/diagnostics13213303
_version_ 1785135476017987584
author Lawaetz, Mads
Christensen, Anders
Juhl, Karina
Lelkaitis, Giedrius
Karnov, Kirstine
Carlsen, Esben Andreas
Charabi, Birgitte W.
Loft, Annika
Czyzewska, Dorota
von Buchwald, Christian
Kjaer, Andreas
author_facet Lawaetz, Mads
Christensen, Anders
Juhl, Karina
Lelkaitis, Giedrius
Karnov, Kirstine
Carlsen, Esben Andreas
Charabi, Birgitte W.
Loft, Annika
Czyzewska, Dorota
von Buchwald, Christian
Kjaer, Andreas
author_sort Lawaetz, Mads
collection PubMed
description The detection of lymph node metastases is a major challenge in oral and oropharyngeal squamous cell carcinoma (OSCC and OPSCC). (68)Ga-NOTA-AE105 is a novel positron emission tomography (PET) radioligand with high affinity to urokinase-type plasminogen activator receptor (uPAR), a receptor expressed on the surfaces of tumor cells. The aim of this study was to investigate the diagnostic value of uPAR-PET/CT (computerized tomography) in detecting regional metastatic disease in patients with OSCC and OPSCC compared to the current imaging work-up. In this phase II trial, patients with OSCC and OPSCC referred for surgical treatment were prospectively enrolled. Before surgery, (68)Ga-NOTA-AE105 uPAR-PET/CT was conducted, and SUVmax values were obtained from the primary tumor and the suspected lymph nodes. Histology results from lymph nodes were used as the standard of truth of metastatic disease. The diagnostic values of (68)Ga-uPAR-PET/CT were compared to conventional routine preoperative imaging results (CT and/or MRI). The uPAR expression in resected primary tumors and metastases was determined by immunohistochemistry and quantified digitally (H-score). A total of 61 patients underwent uPAR-PET/CT. Of the 25 patients with histologically verified lymph node metastases, uPAR-PET/CT correctly identified regional metastatic disease in 14 patients, with a median lymph node metastasis size of 14 mm (range 3–27 mm). A significant correlation was found between SUVmax and the product of the H-score and tumor depth (r = 0.67; p = 0.003). The sensitivity and specificity of uPAR-PET/CT in detecting regional metastatic disease were 56% and 100%, respectively. When added to CT/MRI, uPAR-PET was able to upstage 2/11 (18%) of patients with occult metastases and increase the sensitivity to 64%. The sensitivity and specificity of (68)Ga-NOTA-AE105 uPAR-PET/CT were equivalent to those of CT/MRI. The significant correlation between SUVmax and uPAR expression verified the target specificity of (68)Ga-NOTA-AE105. Despite the target specificity, the sensitivity of imaging is too low for nodal staging and it cannot replace neck dissection.
format Online
Article
Text
id pubmed-10649042
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106490422023-10-25 Diagnostic Value of Preoperative uPAR-PET/CT in Regional Lymph Node Staging of Oral and Oropharyngeal Squamous Cell Carcinoma: A Prospective Phase II Trial Lawaetz, Mads Christensen, Anders Juhl, Karina Lelkaitis, Giedrius Karnov, Kirstine Carlsen, Esben Andreas Charabi, Birgitte W. Loft, Annika Czyzewska, Dorota von Buchwald, Christian Kjaer, Andreas Diagnostics (Basel) Article The detection of lymph node metastases is a major challenge in oral and oropharyngeal squamous cell carcinoma (OSCC and OPSCC). (68)Ga-NOTA-AE105 is a novel positron emission tomography (PET) radioligand with high affinity to urokinase-type plasminogen activator receptor (uPAR), a receptor expressed on the surfaces of tumor cells. The aim of this study was to investigate the diagnostic value of uPAR-PET/CT (computerized tomography) in detecting regional metastatic disease in patients with OSCC and OPSCC compared to the current imaging work-up. In this phase II trial, patients with OSCC and OPSCC referred for surgical treatment were prospectively enrolled. Before surgery, (68)Ga-NOTA-AE105 uPAR-PET/CT was conducted, and SUVmax values were obtained from the primary tumor and the suspected lymph nodes. Histology results from lymph nodes were used as the standard of truth of metastatic disease. The diagnostic values of (68)Ga-uPAR-PET/CT were compared to conventional routine preoperative imaging results (CT and/or MRI). The uPAR expression in resected primary tumors and metastases was determined by immunohistochemistry and quantified digitally (H-score). A total of 61 patients underwent uPAR-PET/CT. Of the 25 patients with histologically verified lymph node metastases, uPAR-PET/CT correctly identified regional metastatic disease in 14 patients, with a median lymph node metastasis size of 14 mm (range 3–27 mm). A significant correlation was found between SUVmax and the product of the H-score and tumor depth (r = 0.67; p = 0.003). The sensitivity and specificity of uPAR-PET/CT in detecting regional metastatic disease were 56% and 100%, respectively. When added to CT/MRI, uPAR-PET was able to upstage 2/11 (18%) of patients with occult metastases and increase the sensitivity to 64%. The sensitivity and specificity of (68)Ga-NOTA-AE105 uPAR-PET/CT were equivalent to those of CT/MRI. The significant correlation between SUVmax and uPAR expression verified the target specificity of (68)Ga-NOTA-AE105. Despite the target specificity, the sensitivity of imaging is too low for nodal staging and it cannot replace neck dissection. MDPI 2023-10-25 /pmc/articles/PMC10649042/ /pubmed/37958201 http://dx.doi.org/10.3390/diagnostics13213303 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lawaetz, Mads
Christensen, Anders
Juhl, Karina
Lelkaitis, Giedrius
Karnov, Kirstine
Carlsen, Esben Andreas
Charabi, Birgitte W.
Loft, Annika
Czyzewska, Dorota
von Buchwald, Christian
Kjaer, Andreas
Diagnostic Value of Preoperative uPAR-PET/CT in Regional Lymph Node Staging of Oral and Oropharyngeal Squamous Cell Carcinoma: A Prospective Phase II Trial
title Diagnostic Value of Preoperative uPAR-PET/CT in Regional Lymph Node Staging of Oral and Oropharyngeal Squamous Cell Carcinoma: A Prospective Phase II Trial
title_full Diagnostic Value of Preoperative uPAR-PET/CT in Regional Lymph Node Staging of Oral and Oropharyngeal Squamous Cell Carcinoma: A Prospective Phase II Trial
title_fullStr Diagnostic Value of Preoperative uPAR-PET/CT in Regional Lymph Node Staging of Oral and Oropharyngeal Squamous Cell Carcinoma: A Prospective Phase II Trial
title_full_unstemmed Diagnostic Value of Preoperative uPAR-PET/CT in Regional Lymph Node Staging of Oral and Oropharyngeal Squamous Cell Carcinoma: A Prospective Phase II Trial
title_short Diagnostic Value of Preoperative uPAR-PET/CT in Regional Lymph Node Staging of Oral and Oropharyngeal Squamous Cell Carcinoma: A Prospective Phase II Trial
title_sort diagnostic value of preoperative upar-pet/ct in regional lymph node staging of oral and oropharyngeal squamous cell carcinoma: a prospective phase ii trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649042/
https://www.ncbi.nlm.nih.gov/pubmed/37958201
http://dx.doi.org/10.3390/diagnostics13213303
work_keys_str_mv AT lawaetzmads diagnosticvalueofpreoperativeuparpetctinregionallymphnodestagingoforalandoropharyngealsquamouscellcarcinomaaprospectivephaseiitrial
AT christensenanders diagnosticvalueofpreoperativeuparpetctinregionallymphnodestagingoforalandoropharyngealsquamouscellcarcinomaaprospectivephaseiitrial
AT juhlkarina diagnosticvalueofpreoperativeuparpetctinregionallymphnodestagingoforalandoropharyngealsquamouscellcarcinomaaprospectivephaseiitrial
AT lelkaitisgiedrius diagnosticvalueofpreoperativeuparpetctinregionallymphnodestagingoforalandoropharyngealsquamouscellcarcinomaaprospectivephaseiitrial
AT karnovkirstine diagnosticvalueofpreoperativeuparpetctinregionallymphnodestagingoforalandoropharyngealsquamouscellcarcinomaaprospectivephaseiitrial
AT carlsenesbenandreas diagnosticvalueofpreoperativeuparpetctinregionallymphnodestagingoforalandoropharyngealsquamouscellcarcinomaaprospectivephaseiitrial
AT charabibirgittew diagnosticvalueofpreoperativeuparpetctinregionallymphnodestagingoforalandoropharyngealsquamouscellcarcinomaaprospectivephaseiitrial
AT loftannika diagnosticvalueofpreoperativeuparpetctinregionallymphnodestagingoforalandoropharyngealsquamouscellcarcinomaaprospectivephaseiitrial
AT czyzewskadorota diagnosticvalueofpreoperativeuparpetctinregionallymphnodestagingoforalandoropharyngealsquamouscellcarcinomaaprospectivephaseiitrial
AT vonbuchwaldchristian diagnosticvalueofpreoperativeuparpetctinregionallymphnodestagingoforalandoropharyngealsquamouscellcarcinomaaprospectivephaseiitrial
AT kjaerandreas diagnosticvalueofpreoperativeuparpetctinregionallymphnodestagingoforalandoropharyngealsquamouscellcarcinomaaprospectivephaseiitrial